ATE541584T1 - Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer - Google Patents

Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer

Info

Publication number
ATE541584T1
ATE541584T1 AT06850448T AT06850448T ATE541584T1 AT E541584 T1 ATE541584 T1 AT E541584T1 AT 06850448 T AT06850448 T AT 06850448T AT 06850448 T AT06850448 T AT 06850448T AT E541584 T1 ATE541584 T1 AT E541584T1
Authority
AT
Austria
Prior art keywords
metastasis
endogene
inhibitors
person
met
Prior art date
Application number
AT06850448T
Other languages
English (en)
Inventor
Fariba Nayeri
Tayeb Nayeri
Original Assignee
Fariba Nayeri
Tayeb Nayeri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fariba Nayeri, Tayeb Nayeri filed Critical Fariba Nayeri
Application granted granted Critical
Publication of ATE541584T1 publication Critical patent/ATE541584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06850448T 2005-11-16 2006-11-16 Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer ATE541584T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73733105P 2005-11-16 2005-11-16
PCT/IB2006/003944 WO2007110698A2 (en) 2005-11-16 2006-11-16 Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors

Publications (1)

Publication Number Publication Date
ATE541584T1 true ATE541584T1 (de) 2012-02-15

Family

ID=38541481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850448T ATE541584T1 (de) 2005-11-16 2006-11-16 Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer

Country Status (5)

Country Link
US (1) US20090068179A1 (de)
EP (1) EP1957102B1 (de)
CN (1) CN101360511A (de)
AT (1) ATE541584T1 (de)
WO (1) WO2007110698A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US11564915B2 (en) * 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
EP3042192A4 (de) * 2013-09-04 2017-04-26 Sten Ohlson Schwache affinitätschromatografie
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
EP1320384B1 (de) * 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
DK1687636T3 (da) * 2003-09-29 2009-05-11 Peas Inst Ab Hurtig bestemmelse af forskellige former for hepatocytvækstfaktor (HGF) i legemsvæsker
CA2548282A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価

Also Published As

Publication number Publication date
CN101360511A (zh) 2009-02-04
WO2007110698A2 (en) 2007-10-04
EP1957102B1 (de) 2012-01-18
WO2007110698A3 (en) 2008-02-21
EP1957102A2 (de) 2008-08-20
US20090068179A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
PL1893196T5 (pl) Związek diarylohydantoinowy
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DE602005019144D1 (de) Verfahren zur schmerzbehandlung in knochenkrebs du
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602004022982D1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE548359T1 (de) Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE50207332D1 (de) Phosphonite, ihre verwendung als ligand in übergangsmetall komplexen und verfahren zur herstellung von nitrilen
ATE541584T1 (de) Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer
DE602005023452D1 (de) Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte
TW200716132A (en) Novel chemical compounds
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
ATE389183T1 (de) Zytokapazität-verfahren
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz